FDA Delays Stoke’s Request for Expedited Approval of Epilepsy Drug

Stoke Therapeutics announced that the Food and Drug Administration (FDA) has decided not to approve an expedited submission for its treatment targeting severe epilepsy. This decision, communicated on Sunday, follows a meeting held in December 2023, where the FDA acknowledged Stoke’s request regarding zorevunersen, a drug specifically aimed at treating Dravet syndrome.

In an interview, Stoke CEO Ian Smith revealed that while the FDA did not fully reject the proposal, it did request additional information from the company. The regulators indicated that they are open to discussions about the possibility of Stoke filing for zorevunersen later this year, rather than waiting for the completion of the ongoing Phase 3 study, which is expected to conclude in the middle of 2027.

The FDA’s request for more information highlights the complexities involved in drug approval processes, particularly for treatments addressing serious health conditions like Dravet syndrome. Stoke is currently evaluating its options and plans to determine a regulatory pathway for zorevunersen by mid-year.

The company remains committed to advancing the development of this potentially transformative treatment. Further discussions with the FDA are expected, which may pave the way for a more streamlined approval process. As the pharmaceutical landscape evolves, Stoke’s ability to adapt to regulatory feedback will be crucial in its efforts to bring zorevunersen to patients in need.

As the situation develops, stakeholders in the epilepsy treatment community will be closely monitoring the outcomes of these ongoing discussions between Stoke Therapeutics and the FDA.